Who should avoid GLP-1 weight loss treatment in Orlando?
Some medical histories rule out a particular GLP-1 medicine. Others call for additional assessment or a different treatment. The exact product, reason for use and current health circumstances determine which advice applies.
Medical reasons a particular GLP-1 medicine must be avoided
Some findings make a particular prescription unsuitable even with careful monitoring. These formal restrictions are called contraindications. Among current weight loss medication options, Wegovy, Zepbound and Foundayo have contraindications for a personal or family history of medullary thyroid carcinoma, or MTC, and for a person who has multiple endocrine neoplasia syndrome type 2, or MEN2. These warnings do not mean every thyroid diagnosis is the same.
A previous serious allergic reaction also matters. Wegovy treatment is contraindicated after a serious reaction to semaglutide or its ingredients; Zepbound treatment has the corresponding restriction for tirzepatide or its ingredients. Record the product, reaction and treatment you received. Nausea alone is not the same as a serious allergy, but neither should be left out of your history.
Pregnancy requires a separate decision, even though it is not listed under the formal contraindications for these products. Weight loss treatment is not appropriate during pregnancy. Contact the prescriber promptly if pregnancy occurs; weight-management labeling directs stopping treatment. When a medicine is prescribed for another condition, such as diabetes, an appropriate replacement care plan also needs attention. A website checklist cannot resolve those decisions.
Absolute
The screening
What the screening actually asks
Family history
Thyroid cancer and endocrine syndromes in particular. If you are unsure, it is worth asking relatives before the appointment rather than guessing.
Personal history
Pancreatitis, gallbladder disease, severe gastrointestinal conditions and any previous reaction to a GLP-1.
Current medication
Especially diabetes treatment, thyroid medication and anything with strict absorption timing.
Pregnancy and planning
Whether pregnancy is possible now or planned, and what contraception is in place.
Care, not exclusion
When GLP-1 precautions require more than a routine assessment
A history of pancreatitis, gallbladder disease, kidney problems or diabetes-related eye disease needs a detailed review. Bring available diagnoses, dates and treatment records to your weight loss eligibility assessment. A past diagnosis does not produce one answer for every product, and active symptoms may need attention before weight treatment is considered. Severe gastroparesis is particularly important: Wegovy, Zepbound and Foundayo are not recommended for this severe stomach-emptying disorder. Calling it a precaution does not mean treatment should proceed. The qualifying health conditions that support a prescription do not cancel its risks.
The review also needs your current prescriptions, supplements, pregnancy plans, breastfeeding status and upcoming procedures. Some medicines increase low-blood-sugar risk when combined with insulin or a sulfonylurea; oral products can have additional interactions. The oral GLP-1 treatment guide explains why a tablet needs its own assessment. Under physician-supervised weight loss care, ask which findings require further information, which make the proposed medicine unsuitable and what alternatives remain. Slower dose increases cannot remove a contraindication. This site supplies information, not medical clearance or a guarantee that a provider will prescribe.
Previous poor reactionSlower titration
Pancreas or gallbladderCloser watch
GI conditionsCase by case
Safety
The rest of the safety picture
Side effects, interactions and what to do about each.
Questions about GLP-1 safety before a treatment decision
The distinction between an exclusion and a precaution depends on the actual medicine and your medical history.
No. An underactive thyroid is not the same diagnosis as medullary thyroid carcinoma or MEN2. The clinician needs the exact condition and any relevant family history, rather than a general description of a thyroid problem. If a relative had thyroid cancer and you do not know the type, say so and seek clarification before a prescribing decision. Other parts of your history still need assessment.
There is no single answer for every product or formulation. Wegovy tablets are not recommended during breastfeeding, and Foundayo is not recommended for nursing women. Wegovy injection and Zepbound labeling instead call for weighing breastfeeding benefits, the mother's clinical need and possible risks. Limited milk data do not establish safety for an infant. Review the exact medicine and treatment purpose with the prescribing and maternity clinicians before starting or continuing.
Give the prescriber the diagnosis, when it happened, whether the cause was identified and any continuing symptoms or treatment. These histories need clinical judgment; they should not be treated as either automatic approval or a universal ban on every GLP-1 medicine. Current severe or persistent abdominal pain, especially with vomiting, calls for urgent medical assessment rather than an eligibility inquiry.
It means the prescribing and procedure teams need to know what you take. Delayed stomach emptying can increase the risk of stomach contents entering the lungs during general anesthesia or deep sedation. Tell them the exact product, last dose and any digestive symptoms. They should provide individualized instructions; do not apply a generic medication pause from an online checklist.
A lower dose does not remove a contraindication such as MEN2 or a previous serious allergy to that medicine. It also does not establish that treatment is appropriate when a label says it is not recommended for a condition. Dose decisions belong to the prescriber after the safety review. Ask why the proposed option is suitable and what other treatments could address your goals.
